DYADIC INTERNATIONAL INC
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
DYAI$0.37-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits and Financial Statement Schedules
| Item 15. | Financial Statement and Exhibits |
|---|
(a) Financial Statement
Our financial statements and related notes thereto are listed and included in this Annual Report on Form 10-K beginning on page F-1.
(b) Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit No. | Description of Exhibit | Form | Original No. | Date Filed | Filed Herewith |
| 3.1# | Restated Certificate of Incorporation dated November 1, 2004 | 10-12G | 3.1 | January 14, 2019 | |
| 3.2# | Third Amended and Restated Bylaws dated March 28, 2023 | 8-K | 3.1 | March 29, 2023 | |
| 4.1# | Specimen Stock Certificate Evidencing Shares of Common Stock | 10-12G | 4.1 | January 14, 2019 | |
| 4.2# | Description of Registered Securities | 10-K | 4.2 | March 30, 2020 | |
| 4.3# | Senior Secured Convertible Promissory Note due March 8, 2027, dated March 8, 2024 | 8-K | 4.1 | March 11, 2024 | |
| 10.1**# | Dyadic International, Inc. 2011 Equity Incentive Plan | 10-12G | 10.2 | January 14, 2019 | |
| 10.2**# | Dyadic International, Inc. 2021 Equity Incentive Plan | S-8 | 4.3 | August 12, 2021 | |
| 10.2.1** | Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan | x | |||
| 10.2.2** | Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2021 Equity Incentive Plan | x | |||
| 10.3**# | Form of Restricted Stock Unit Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan | 10-12G | 10.3 | January 14, 2019 | |
| 10.4**# | Form of Stock Option Agreement Pursuant to the Dyadic International, Inc. 2011 Equity Incentive Plan | 10-12G | 10.4 | January 14, 2019 | |
| 10.5**# | Employment Agreement, dated June 16, 2016, and First Amendment dated January 23, 2017, by and between Dyadic International, Inc. and Mark A. Emalfarb | 10-12G | 10.5 | January 14, 2019 | |
| 10.5.1**# | Second Amendment to Employment Agreement between Dyadic International, Inc. and Mark A. Emalfarb, dated as of November 12, 2019 | 8-K | 10.1 | November 13, 2019 | |
| 10.6**# | Consulting Agreement, dated January 1, 2016, by and between Dyadic Netherlands B.V. and Sky Blue Biotech kft on behalf of Ronen Tchelet | 10-12G | 10.7 | January 14, 2019 | |
| 10.7**# | Compensation Letter, dated March 26, 2018, by and between Dyadic International, Inc. and Ping W. Rawson | 10-12G | 10.9 | January 14, 2019 | |
| 10.8**# | Employment Agreement between Dyadic International Inc. and Joseph Hazelton dated November 9, 2021 | 8-K | 10.1 | November 9, 2021 | |
| 10.9**# | Form of Director and Officer Indemnification Agreement | 10-12G | 10.10 | January 14, 2019 | |
| 10.10# | Lease Agreement with Jupiter Harbour Office, LLC dated August 19, 2023 | 10-Q | 10.1 | November 8, 2023 | |
| 10.11†# | Pharma License Agreement with Danisco US, Inc. dated December 31, 2015 | 10-12G | 10.12 | January 14, 2019 | |
| 10.12†# | Commission Contract with VTT Technical Research Centre of Finland Ltd dated September 2, 2016 | 10-12G | 10.13 | January 14, 2019 | |
| 10.12.1†# | Commission Contract with VTT Technical Research Centre of Finland Ltd dated June 28, 2019 | 8-K | 10.1 | July 5, 2019 | |
| 10.13†# | Service Framework Agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. dated June 30, 2017 | 10-Q | 10.2 | November 8, 2023 | |
| 10.13.1†# | Amendment No. 1 dated July 26, 2021, to the Service Framework Agreement dated June 30, 2017 | 8-K | 10.3 | July 27, 2021 | |
| 10.14†# | License Agreement with VTT Technical Research Centre of Finland Ltd dated July 17, 2017 | 10-12G | 10.17 | January 14, 2019 | |
| 10.15†# | Joint Development Agreement with Leprino Foods Company, dated May 12, 2022 | 8-K | 10.1 | May 11, 2022 | |
| 10.16†# | Research and Commercialization Collaboration Agreement with Serum Institute of India Pvt. Ltd., dated May 7, 2019 | 8-K | 10.1 | May 8, 2019 | |
| 10.17†# | Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated May 5, 2019 | 8-K | 10.1 | May 8, 2019 | |
| 10.17.1†# | Amended and Restated Non-Exclusive Sublicense Agreement among Dyadic International, Inc., Alphazyme, LLC, dated June 24, 2020 | 8-K | 10.1 | June 29, 2020 | |
| 10.18# | Master Services Agreement and Work Order, between Dyadic International (USA), Inc. and CR2O B.V., Dated May 28, 2021 | 8-K | 10.1 | June 3, 2021 | |
| 10.19†# | Alphazyme Sale Agreement dated January 18, 2023 | 8-K | 10.1 | January 23, 2023 | |
| 10.20†# | RUBIC License Agreement dated April 6, 2023 | 8-K | 10.1 | April 6, 2023 | |
| 10.21†# | Inzyme Development and Exclusive License Agreement, effective September 18, 2023 | 8-K | 10.1 | September 19, 2023 | |
| 10.22# | Securities Purchase Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 | 8-K | 10.1 | March 11, 2024 | |
| 10.23# | Registration Rights Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 | 8-K | 10.2 | March 11, 2024 | |
| 10.24# | Security Agreement Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 | 8-K | 10.3 | March 11, 2024 | |
| 10.25# | Subsidiary Guarantee Relating to the Senior Secured Convertible Promissory Note dated March 8, 2024 | 8-K | 10.4 | March 11, 2024 | |
| 21.1 | Subsidiaries of the Registrant | x | |||
| 23.1 | Consent of Independent Registered Public Accounting Firm - Crowe LLP | x | |||
| 23.2 | Consent of Independent Registered Public Accounting Firm - Mayer Hoffman McCann P.C. | x | |||
| 24.1 | Power of Attorney (included on signature page) | ^ | |||
| 31.1 | Certification of Chief Executive Officer of Dyadic International, Inc, Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | x | |||
| 31.2 | Certification of Chief Financial Officer of Dyadic International, Inc. Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | x | |||
| 32.1^ | Certification of Chief Executive Officer of Dyadic International, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 32.2^ | Certification of Chief Financial Officer of Dyadic International, Inc. Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | ||||
| 97 | Policy Related to Recovery of Erroneously Awarded Compensation | ||||
| 101.INS | Inline XBRL Instance Document | x | |||
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document | x | |||
| 101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | x | |||
| 101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | x | |||
| 101.LAB | Inline XBRL Taxonomy Extension Labels Linkbase Document | x | |||
| 101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | x | |||
| 104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) | ||||
Legend:
** Identifies a management contract or compensatory plan or arrangement.
† Certain provisions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.